A patient with GCT which of the following is false:-
**Core Concept**
GCT, or Gonadotropin-Releasing Hormone (GnRH) - secreting tumors, are a type of neuroendocrine tumor that can lead to excessive secretion of gonadotropins, resulting in hypergonadotropic hypogonadism. This condition can be managed with GnRH agonists, which initially stimulate and eventually downregulate GnRH receptors.
**Why the Correct Answer is Right**
GnRH agonists, such as leuprolide, initially stimulate GnRH receptors, leading to an increase in gonadotropin secretion. However, with continued exposure, GnRH receptors become desensitized, resulting in decreased gonadotropin secretion and a decrease in estrogen levels in postmenopausal women or testosterone levels in men. This downregulation of GnRH receptors is the therapeutic mechanism behind the use of GnRH agonists in treating GCT.
**Why Each Wrong Option is Incorrect**
**Option A:** This statement is true as GnRH agonists can cause an initial flare-up of gonadotropin secretion, which can worsen symptoms in some patients.
**Option B:** This statement is false. GnRH agonists do not directly stimulate the growth of GCT; instead, they act by reducing gonadotropin secretion, which can slow tumor growth.
**Option C:** This statement is true as GnRH agonists can cause a decrease in estrogen levels in postmenopausal women or testosterone levels in men, leading to hot flashes and other symptoms.
**Clinical Pearl / High-Yield Fact**
GnRH agonists can cause an initial flare-up of gonadotropin secretion, which can worsen symptoms in some patients, making it essential to initiate therapy with a lower dose and gradually increase as needed.
**Correct Answer: B. GnRH agonists do not directly stimulate the growth of GCT; instead, they act by reducing gonadotropin secretion, which can slow tumor growth.**